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These studies were undertaken to help define a possible viral role in the etiology 
of the lupus like disease of NZ mice. This disease,  characterized by antinuclear 
antibodies  (ANA) ~ and  immune  complex type glomerulonephritis,  is  found  in 
(NZB  x  NZW)F~  and  NZB  mice  (1)  and  closely  resembles  systemic  lupus 
erythematosus (SLE)  of man.  In addition, Coombs' type antibodies and associ- 
ated  hemolytic  anemia  occur  in  the  NZB  mice.  The  ANA  appear  central  in 
murine  lupus  since  they  arise  early  and  are  of  primary  importance  in  the 
production of glomerulonephritis (2).  Of the various possible sources of immuno- 
genic  material  which  might  initiate  an  ANA response,  oncornaviruses  which 
infect most mice and present an unusually wide spectrum of foreign nucleic acids 
to  the  host  would  seem  to  be  ideal  candidates.  The  immunogenicity  of 
oncornaviruses is  evidenced by the fact that  (NZB  ×  NZW)F1 mice spontane- 
ously  make  antibody  to  every recognizable  macromolecule synthesized  during 
their replication  (3,  4). 
The presence of murine leukemia viruses (MuLV) in NZ mice is well established, and an 
immunologic hyperresponsiveness of NZB and (NZB x  NZW)F1 mice to these agents has 
been  described  (5-7).  Both NZB and  (NZB  x  NZW)F1 mice exhibit  seropositivity for 
Gross murine leukemia virus antigen  (GSA) early in life,  and this  is followed  by rising 
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titers  of free  GSA antibody  which  suggest  immune  elimination  of GSA with  associated 
circulating immune complexes preceding and during the development of glomerulonephri- 
tis (5, 6). In further support of a  role for antigen-antibody  complexes in this glomerulone- 
phritis,  fluorescent  antibody  studies  of glomerulonephritic  kidneys  have  demonstrated 
MuLV  group  antigen  in  NZB  mice  (5)  and  DNA-anti-DNA  complexes  in  (NZB  x 
NZW)FI mice (7). In addition,  elution of renal antibody  has demonstrated  concentration 
of GSA antibody  in  the  kidneys  of NZB  mice (6)  and  antibody  to nucleoprotein  and to 
Gross virus antigens  (7)  in the kidneys of (NZB  x  NZW)F1 mice. 
If in fact MuLV is the cause of murine lupus, it might be possible to mimic the 
spontaneous  disease  by  infecting susceptible  but  otherwise  normal  strains  of 
mice with  such  an  agent.  However,  attempts  to  produce a  similar disease in 
healthy  mice  by  transfer  of  cell-free  filtrates  from  NZ  mice  have  yielded 
conflicting and inconclusive results. Two positive reports by Mellors and Huang 
describe limited success in producing glomerulonephritis and hemolytic anemia 
with transfers of cell-free filtrates of NZB lymphoma or aged normal spleens (8, 
9).  In contrast,  Holmes et al. (10),  East and Prosser (11),  Howie and Heyer (1) 
and East et al. (12) were unable to produce any immunologic abnormalities with 
transfers of NZB cell-free material,  although whole spleen cells would transfer 
Coombs' positivity and lymphoma in certain situations. In this report we show 
that purified virus obtained from a NZB thymoblastoid line (13) induced ANA, 
glomerulonephritis,  and  thymoblastic  lymphoma when injected into  newborn 
(BALB/c x  NZB)F~ mice. 
Materials  and  Methods 
Cells and  Viruses.  All cells were grown in Eagle's MEM supplemented with sodium pyruvate, 
nonessential amino acids,  10% fetal calf serum,  and antibiotics (Flow Laboratories, Inc., Rockville, 
Md.),  NIH Swiss 3T3, BALB/c 3T3,  and XC cells were obtained from Dr. V. Klement, Children's 
Hospital,  Los  Angeles,  Calif.  Secondary  (BALB/c  x  NZB)F1 embryo  cultures  were  prepared  as 
needed in our laboratory. The isolation and properties of Scripps Clinic Research Foundation (SCRF) 
60A°NZB lymphoblasts have been previously described (13). The SCRF 60A cells were grown from 
a density of 2  x  10'-2  x  105 to a maximum density of 2 x  10 e cells/ml. 
Small volumes of cells (20 ml) were grown as stationary cultures in Falcon flasks (Falcon Plastics, 
Div. of BioQuest, Oxnard, Calif.). Large volumes of cells (200 ml to 1 liter) were grown in Erlenmeyer 
flasks on gyrotory shakers  as previously described (13). 
Scripps  leukemia  virus  (SLV 60A)  was  purified from supernatant  fluids of SCRF 60A  cells as 
previously described (13) and stored at -195°C in liquid nitrogen until use. AKR MuLV, which had 
been  purified  by  sedimentation  in  sucrose  gradients  to  its  isopycnic  density  (1.16  g/cm-S),  was 
prepared by Electro-Nucleonics, Inc., Bethesda, Md. (no. 221-79) and supplied to us by the National 
Cancer Institute,  Bethesda, Md. For some experiments, virus was inactivated by addition of/3-pro- 
piolactone (/~PL) (Sigma Chemical Co., St. Louis, Mo.) to a  concentration of 10 mM at 4°C for 2 h 
and overnight incubation at 37 °C (SLV 60A BPL). 
Infectious virus titers were determined by a modification (14) of the XC test (15} in Linbro dispo 
trays (Linbro Chemical Co., New Haven, Conn.} or in 60-mm petri dishes. Linbro trays were seeded 
with 2 x  104 substrate cells/well. The next day the substrate cells were treated with DEAE-cellulose 
dextran (Sigma Chemical Co.) and 0.2 ml of each virus dilution was inoculated into four wells. Fresh 
media  was  added  after  2-3  days,  and  after  an  additional  2-3  days  the substrate  cells were  UV 
irradiated  and  overlaid with  10 ~ XC  cells. 2-3 days  later the cells were fixed and  the number of 
syncytia  counted.  The  virus  titer  was  calculated  by  the  method  of Reed  and  Muench  (16)  and 
expressed as tissue culture infective dose (TCID~0)/ml. 1030  IMMUNOPATHOGENICITY AND ONCOGENICITY IN MICE 
Inoculated Animals. 
VIRus INOCULATION.  BALB/c and C3H mice were obtained from Strong Laboratories, San Diego, 
Calif. NZB mice were from the Scripps colony. (BALB/c ×  NZB)F1 hybrids were bred in the Scripps 
vivarium. AKR/J mice were obtained from Jackson Laboratories, Bar Harbor, Maine. Animals were 
provided water and lab chow. 
(BALB/c x  NZB)F1 mice were inoculated within 24 h of birth or at 6 wk of age with the designated 
dose of virus (prepared by dilution of a standard virus pool). Experimental animals were divided into 
the groups as indicated in Table I. All mice were weighed and bled from the retro-orbital plexus at 
4-wk intervals. 
SEROLOOIC STUmES.  Since the emphasis of this study was on the immunologic consequences of 
SLV infection, we chose to follow the infection by measuring the serum Mu gs-1 levels. This protein, 
the major structural component of the virion, should best represent the antigenic load resulting from 
the infection and not be affected by variations in the production of infectious virus vs. noninfectious 
viral products. 
TABLE  I 
Experimental  Groups 
No. male/ 
Group  Inoculum  Dose  Age of recipient  no. female 
l0 B  SLV 60A virus  l0 s TCID~0  Birth  8/7 
102  ......  10 ~  ....  8/12 
10'  ......  10'  ....  10/12 
10 °  ......  10 °  ....  14/8 
10-'  ......  10-'  ....  10/8 
10 -2  ......  10 -2  ....  4/9 
A  AKR virus  l0 B  ....  7/12 
I  SLV 60A ~PL*  103 TCIDs0~  11/7 
N  None  --  --  5/10 
DV  SLV 60A virus  103 TCIDs0  6 wk  8/7 
Virus  doses  are  based  on  dilution  of aliquots  from  a  standard  pool;  titers  are  expressed as 
infectivity for Swiss 3T3 cells. 
* SLV 60A virus which had been inactivated with BPL. 
Equivalent titer before inactivation. 
Sera were analyzed for Mu gs-1  by a radioimmunoassay that is a modification of the procedures 
described by Oroszlan et al.  (17)  and Parks and Scolnick (18).  ANA titers were determined by the 
indirect fluorescent antibody technique (IFA);  sections of mouse kidney were used  as the target 
tissue.  ANA  titers  were  determined  by  endpoint  dilution,  and  the  geometric  mean  titer  was 
calculated. Mice were examined for anti-RBC antibodies by the direct Coombs' test with anti-Mu Ig 
which had been absorbed with RBCs before use. For the Coombs' test, RBCs from 8- to 12-mo old 
NZB mice were used as positive controls and RBCs from 2-too old C3H/St mice were used as negative 
controls. 
HISTOLOGIC STUDIES.  Moribund mice were anesthetized with ether and exsanguinated. WBC and 
RBC counts were determined on a  Coulter counter (Coulter Electronics, Inc., Fine Particle Group, 
Hialeah,  Fla.) and blood smears were prepared for morphologic examination. Spleen weights were 
determined and histologic sections of heart, lung, liver, kidney, bowel, spleen, thymus, lymph node, 
and gonad were stained with hematoxylin and eosin (H & E) or periodic acid-Schiff (PAS) before 
microscopic examination. 
Rabbit antibody against the 3rd component of routine complement (C3)  was prepared by using a 
zymosan C complex as antigen (19). Only those rabbit sera that produced one precipitin line (against 
whole mouse serum) when analyzed by immunoelectrophoresis  and Ouchterlony gel diffusion were 
used.  Antisera  were  partially  purified  and  concentrated  by  precipitation  with  50%  saturated CROKER, DEL VILLANO, JENSEN, LERNER, AND DIXON  1031 
ammonium sulfate (SAS), pH 7,4. Conjugation of globulin  with fluorescein  isothiocyanate (FITC) was 
performed by  the  dialysis method of Clark and  Shepard (20); the  FITC-labeled globulin was 
fractionated on DEAE-cellulose, and  the  material eluting at 0.05 M NaCl, 0.0175 M potassium 
phosphate,  pH  7.4  was  used, Goat antimurine Fab  was  provided by  Dr.  James  C.  Clagett 
(Department of Microbiology and  Immunology, University of Washington School of Medicine, 
Seattle, Wash.). 
Guinea pig and rabbit anti-Mu gs-1 were provided  by Dr. Raymond Gilden of Flow  Laboratories, 
Inc., Bethesda, Md. Before IFA tissue staining, anti-Mu gs-I antisera, and FITC anti-lg sera were 
absorbed with whole murine  sera which  had been concentrated by precipitation  with SAS and coupled 
to Sepharose 4B by cyanogen bromide (21). Cells  and tissues for electron microscopy were fixed in 
phosphate-buffered 2% glutaraldehyde, post  fixed in osmic  acid, dehydrated, embedded in Vestopal 
(Henley & Co., New York), sectioned, and stained with  uranyl acetate and lead citrate. 
Pools of AKR anti-C3H/St  thymocyte  and the reciprocal C3H/St anti-AKR/J  thymocyte  sera were 
prepared by weekly intraperitoneal injections  of i0  ~  thymus cells (22). Pertussis vaccine (Eli Lilly & 
Co., Indianapolis, Ind.), 0.1  ml, was used as adjuvant for the first three injections. Mice were bled 
every  other week after the 6th wk, and sera from 15 to 20 animals were  pooled. As determined  by IFA 
staining, these unabsorbed antisera bound only to the surfaces of viable thymocytes from the strain 
used as immunogen. 
Single cell suspensions of lymphoma tissues were stained for C3H thymocyte  and AKR thymocyte 
antigens by  the  IFA. The  number of stained cells was  determined with  a  Zeiss fluorescence 
microscope (Carl Zeiss, Inc., New  York) adapted for  dark-field fluorescence and  standard  or 
dark-field phase. This microscope allowed the  same field to be  examined by  fluorescence and 
phase-contrast microscopy, so that the fluorescent  to total cell  ratio could easily  be determined. 
Results 
Virus.  SLV 60A virus had a titer of 105 TCIDs0 on Swiss 3T3 cells and 5 ×  104 
on  (BALB/c  ×  NZB)F1 secondary embryo cells. AKR MuLV had a titer of l0 s 
TCID~0 on Swiss 3T3  cells and no demonstrable infectivity on the (BALB/c × 
NZB)F1 cells. SLV 60A ~PL-inactivated gave no detectable infectivity for Swiss 
3T3 cells. MuLV titers throughout the paper are based on infectivity of Swiss 3T3 
cells. 
Inoculated Animals. 
VIROLOGIC STUDIES.  Assays (XC test} for infectious MuLV were performed on 
5% spleen suspensions of four (NZB  ×  BALB/c)F~ mice which had received l0 s 
TCIDso SLV 60A at birth. The animals were sacrificed at 10 wk, at which time 
they were clinically well but had elevated serum Mu gs-1 levels (see next section, 
Serological studies). One of these four animals had a histologically demonstrable 
lymphoma. The virus titers ranged from 2  ×  102 to 2  x  103 TCIDJmg spleen. 
The relationship between virus dose and mortality is shown in Fig. 1. The 50% 
points  for  mortality and  lymphoma are  shown  in  Fig.  2  in  which the  linear 
relationship between the dose of virus, the onset of lymphoma, and mortality are 
demonstrated. 
SEROLOGICAL STUDIES.  Mean serum Mu gs-1 values and SD were calculated for 
each  group  by  month  and  subdivided  by  sex.  The  values  for  uninoculated 
animals (group N) ranged from 29 == 31 ng/ml to 115 ±  110 ng/ml. Similar results 
were obtained for groups I  (inactivated virus),  A  (AKR virus),  and DV  (virus 
injection delayed to 6 wk). 
Serum Mu gs-1  values for groups of animals which received a  dose of virus 
between 10 -2 and 103 TCID~o were plotted as a function of time in Fig. 3.  10- to 1032  IMMUNOPATHOGENICITY  AND ONCOGENICITY  IN  MICE 
100. 
80- 
:~60- 
Z  - 
~40- 
= 
E  = 
¢...>  . 
20- 
=103 
,,,102 
/  ; 
/  o101 
2/'°i  ?  ~ ,~10 
4  8  12  16  20  24 
Time [weeks} 
FIG.  1.  Cumulative  mortality  curves for groups  10  ~-10 ~ TCIDs0,  males and females com- 
bined. All animals in groups 10- ~ survived. 
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FIG.  2.  Linearity  of the  relationship between  virus  dose  and  50%  point for mortality and 
lymphoma. Line shown was obtained by linear regression analysis of the 50% mortality points; 
regression coefficient, r 2 =  0.996,  significance level, P  <  0.005. 
100-fold elevations were evident by 4 wk. There was a  linear dependence of the 
Mu  gs-1  level  on the virus dose as  shown  in  Fig.  4.  Groups of animals  which 
received  between  10 -1  and  102  TCIDs0  of SLV  60A  virus  had  peak  Mu  gs-1 
responses  at  3-4  mo  that  declined  towards  control  levels  afterwards.  The 
subsequent fall in average Mu gs-1 reflected in part the early loss of animals with 
the highest levels of Mu gs-1. 
All  animals  in  the  group  which  received  10 -2  TCIDso  of  SLV  60A  virus 
maintained serum Mu gs-1  levels in the control range. There was no significant 
difference in serum Mu gs-1 between males and females in any group. 
The groups which received no virus, inactivated virus, AKR virus, or SLV 60A 
virus as adults, had peak ANA titers averaging 1. The titers for ANA are given by 
sex in Table II for groups which received 10-2-10a TCID60 of SLV 60A virus. ANA 
titers were highest in groups receiving the highest virus doses (10 a,  102, and 101). 
Females of groups 102 and 101 had the highest peak ANA titers. ANA responses of 
virtually all infected animals peaked at 8-16 wk and then declined. The fall in 
average ANA  titer at  20  and  24 wk  was  not from deaths of animals  with the 
highest titers,  because 24-wk survivors also had peak responses at  12-16 wk. CROKER,  DEL  VILLANO,  JENSEN,  LERNER,  AND DIXON 
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FIG.  3.  Serum  Mu  gs-1 values for  groups  of animals which received  a  dose  of virus from 
10 -s to  10 a TCIDs0.  Group N  was not injected. 
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FIG.  4.  Relationship between  serum Mu  gs-1 and virus dose. The line shown was obtained 
by linear regression analysis of the 1-mo (4 wk) points (r s =  0.64, P  <: 0.05). The 3-mo line (r s = 
0.89, P  <  0.005)  and the 5-mo line (r 2 =  0.75, P  <  0.0D are not shown. 1034  IMMUNOPATHOGENICITY  AND  ONCOGENICITY  IN  MICE 
TABLE II 
ANA  Geometric Mean Titers in  Virus-Inoculated and Control Mice 
Virus dose  Sex  4 wk  8 wk  12 wk  16 wk  20 wk  24 wk 
TCIDso 
l0 s  M  0  15  12  --  --  -- 
F  0  17  12  --  --  -- 
102  M  0  4  10  16  12  25 
F  3  43  18  6  --  -- 
10'  M  0  9  12  17  6  6 
F  1  7  43  4  3  0 
10 °  M  1  4  9  2  3  1 
F  0  13  15  4  7  1 
10 -'  M  0  3  0  1  0  0 
F  0  4  2  1  1  2 
10 -2  M  0  1  0  0  3  0 
F  0  1  1  0  0  0 
None  M  ~ 0  0  0  0  0  0 
F  0  0  0  0  0  0 
Coombs' tests  were performed at 4,  8,  12,  20,  and  24 wk.  Of the  64  animals 
tested  throughout the period of observation from groups which had received no 
virus, inactivated virus, or virus as adults, a single positive result was observed at 
4 wk. Of 113 animals in groups which received 10-5-103 TCIDs0 ofSLV 60A virus, 
7 were positive at 4 wk and 3 of 11 females in the group which received 105 TCIDso 
were positive at 12 wk; no other animals in these groups were Coombs' positive. 
HISTOLOGIC STUDIES.  At autopsy, tumor-bearing animals generally had grossly 
enlarged  lymph  nodes  and  thymuses.  Spleen  weights  were  0.18-7.50  g  in 
tumor-bearing  animals  and  0.05-0.29  g  in  control groups.  In  spite  of palpable 
nodes and spleens and moribund appearance,  less than  25% of the animals had 
more than 10  ×  10 a WBC/mm 3 (infected, 4-163 ×  108 WBC/mmS; control, 2-10 × 
103  WBC/mma).  Histologic  examination  of  the  tumors  and  involved  organs 
showed primarily sheets of uniformly large round lymphoblasts with large nuclei 
and  nucleoli.  5%  of the  tumors  also  had  areas  of reticulum  cell  sarcoma,  with 
mixed  infiltrates  of  plasma  cells,  eosinophiles,  lymphocytes,  and  anaplastic 
reticulum  cells.  Tumor  cells  generally  obliterated  lymph  node  and  thymic 
architecture and infiltrated  the parenchyma of lung, liver, kidney, and ovaries. 
Testes were consistently free of lymphoma. In Fig. 5 a thymus with one involved 
and  one  uninvolved lobe  is  shown.  Essentially,  all  animals  had  lymphomas at 
sacrifice  (Fig.  2).  Electron  microscopy  of  the  tumors  confirmed  the  light 
microscopic appearance  of the  cells  and  demonstrated  C-type virus  in  varying 
degrees of formation, budding from and present near tumor cells  (Fig.  6). 
10 separate  cell suspensions from abdominal tumors were  examined for C3H CROKER, DEL VILLANO,  JENSEN, LERNER,  AND DIXON  1035 
FIG. 5.  Thymus of a  tumor-bearing mouse containing one histologically normal lobe (lower 
left) and one lymphomatous lobe (upper right) (H & E,  ×  50). 
and  AKR  thymic  antigens  by  IFA  staining.  98-100%  of  the  cells  in  these 
suspensions  stained  positively  for  C3H  thymic  antigens,  but  there  was  no 
staining  for  AKR  antigen,  Tumor  cells  were  approximately  twice  as  large  as 
normal thymus cells and had irregular rim staining  (Fig. 7). 
Light  microscope  study of renal  lesions  indicated  a  widespread eosinophilic, 
PAS-positive thickening of the capillary basement lamina (Fig. 8) in comparison 
to controls (Fig. 9). The PAS-positive material also extended into the mesangial 
areas and occasionally formed a confluent mass. In no case was there significant 
proliferation  of  endothelial  or  epithelial  cells.  Subendothelial  electron  dense 
deposits associated with fusion of the epithelial foot processes were seen when the 
kidneys  were  studied  by electron  microscopy  (Fig.  10).  Control  glomeruli  had 
smooth basement lamina  and delicate foot processes (Fig. 11), IgG (Fig.  12) and 
C3  (Fig.  13) were seen within the glomerular capillary walls and mesangia.  Mu 
gs-1 was localized within  glomeruli in  a pattern similar to IgG and C3 and also 
was  seen  in  the  cytoplasm  of  leukemic  infiltrates  (Fig.  14).  Only  minimal 
mesangial localization of IgG was seen in glomeruli of control animals. 1036  IMMUNOPATHOGENICITY  AND ONCOGENICITY  IN  MICE 
FIG. 6.  Electron micrograph showing lymphoma cells from a  lymph node of a  mouse inocu- 
lated with virus. Virus bud is encircled (× 28,000).  Insert shows greater magnification of virus 
bud (×  100,000). 
The incidence of glomerulonephritis in groups which received 10-2-10s  TCIDso 
of virus  is  shown in  Fig.  15.  Since glomerulonephritis was  diagnosed only by 
histologic examination of autopsied animals, its presence in living animals was 
not recognized; therefore, its recorded incidence is a minimum figure. In Fig. 16 
the glomerulonephritis incidence in all groups is expressed as a  function of the 
animal's age at sacrifice; the younger the animal at sacrifice, the greater was the 
likelihood of glomerulonephritis. 
Comparison of Fig. 16 and Table II indicates a coincidence between the peaks 
in ANA response and the greatest glomerulonephritis incidence. However, when CROKER, DEL VILLANO, JENSEN, LERNER, AND DIXON  1037 
FIG.  7.  C3H  normal thymocyte suspension showing (a)  IFA staining for  AKR anti-C3H 
thymocyte surface,  0, antigens and (b) phase  contrast photomicrography  of the same field. 
Panels (c) and (d) prepared as in (a) and (b), respectively, using lymphoma cell suspension (x 
680). 
individual animals were scored for glomerulonephritis and ANA and analyzed by 
the chi-square test for correlation between ANA titer and glomerulonephritis, no 
significant statistical  correlation was  found.  A  greater  percentage of females 
developed  glomerulonephritis than  did  males.  This  sex  difference  was  first 
evident at 12 wk and persisted throughout the period of observation with female 
to male ratios of up to 3:1. 
Discussion 
Inoculation of SLV 60A virus into immunologically  normal, neonatal (BALB/c x 
NZB)F1 mice was followed within a few months by a dose-related development of 
high  levels  of  serum  Mu  gs-1,  high  titers  of ANA,  glomerulonephritis,  and 
lymphoma. In most respects, the immunologic disease consisting of ANA and an 
apparent immune complex glomerulonephritis was similar to the spontaneous 
glomerulonephritis of NZ mice except that its onset was much earlier, i.e., 2-3 
mo vs. 5-6 too. As in NZ mice, the incidence and titers of ANA and incidence of 
glomerulonephritis were  greater  in  females.  The  peak  ANA  titers  were  also 1038  IMMUNOPATHOGENICITY  AND ONCOGENICITY  IN  MICE 
FIG. 8.  Glomerulus, group 102, showing capillary basement lamina thickening (PAS,  ×  500). 
temporally related to  the  peak  incidence of glomerulonephritis. Since normal 
mice or mice injected with inactivated SLV or live AKR viruses did not develop 
these immunologic abnormalities and, since the infected mice developed them 
early and in proportion to the dose of virus given, it seems likely that the virus 
was their cause. 
The linear relationship between virus dilution and subsequent serum Mu gs-1 
suggests that the number of infectious particles determined the magnitude of the 
continuing infection. The spread of infection must have been constrained, since 
the  increase  in  Mu  gs-1  remained proportional  to the  initial dose for several 
months and did not reach a comparable maximum for all groups. One possible 
explanation is that the population of cells susceptible to infection was limited to 
the neonatal period, thus preventing spread of progeny virus to other cells. This is 
in contrast to other chronic viral infections such as lactate dehydrogenase virus. 
Within  4  days  the  marker  serum  protein,  lactate  dehydrogenase,  reached 
constant levels independent of virus dose over six 10-fold dilutions (23). 
The nature of the relationships between SLV infection on the one hand and 
ANA production and development of glomerulonephritis on the other hand are CROKER,  DEL VILLANO,  JENSEN, LERNER,  AND DIXON  1039 
FIG. 9.  Control, group N, 3 mo, showing normal appearance of glomerulus (PAS,  x  500). 
not  entirely  clear  but  several  things  appear  likely.  First,  the  ANA formation 
seems to be a response to a dose-related immunogenic stimulus resulting from the 
viral infection. Whether the immunogen(s) is supplied directly by the virus or is a 
host nuclear substance released as a by-product of infection cannot be said, nor 
has any possible adjuvant action of the oncornavirus on the ANA response been 
evaluated to date. Second, the immune complexes causing the glomerulonephri- 
tis probably include both nuclear  antigenswANA and viral antigens--antiviral 
antibodies.  Analysis of the Ig deposited in the  glomeruli  in this disease reveals 
that  about half of it  reacts  with  nucleoprotein  and  that  an  additional  10-20% 
reacts with oncornavirus antigens  (17).  Qualitative tests of Ig eluates from these 
kidneys  show  the  presence  of antibodies  to  gp  69-70  (S.  J.  Kennel,  personal 
communication,  reverse transcriptase  (Raymond  Gilden,  personal  communica- 
tion),  Mu gs-1 (P. McConahey and F. J. Dixon,  unpublished observations), and 
SLV 60A neutralizing antibodies (F. C. Jensen, unpublished observations). Judg- 
ing from the amount of Mu gs-1 antigen continuously present in the circulation, 
which should be a reasonable index of the antigenic load produced by the virus, 
the total  amount of viral antigen to which the more heavily infected mice were 
exposed over a several month period should have amounted to many milligrams. 1040  IMMUNOPATHOGENICITY  AND ONCOGENICITY IN MICE 
Fro.  10.  Group 10  1, glomerular capillary loop showing subendothelial deposits and fusion of 
epithelial foot processes (×  14,000). 
Thus,  the  size  of the  SLV  infection  could  influence  the  degree  of immune 
complex glomerulonephritis,  both by determining the amount of ANA produc- 
tion and the amount of viral antigen available to form complexes with antiviral 
antibodies. CROKER, DEL VILLANO, JENSEN, LERNER, AND DIXON  1041 
Fro. 11.  Control glomerular capillary loop showing normal structure (× 16,000). 
Our failure to induce a significant amount of Coombs' positivity in any of the 
groups  of  infected  mice  suggests  that  either  the  ANA-glomerulonephritis 
syndrome has an etiology quite different from the Coombs' antibody-hemolytic 
anemia  or  that  (BALB/c  ×  NZB)F~  mice  are  particularly  resistant  to  the 
formation of anti-RBC antibodies. In support of the former, work to be reported 1042  IMMUNOPATHOGENICITY  AND ONCOGENICITY IN MICE 
FIG. 12.  Group  10S,-glomerulus stained  for IgG and showing circumferential staining of the 
glomerular capillaries (x 600). 
elsewhere  indicates this  apparent  etiologic separation  of renal  and hemolytic 
diseases in other murine strains. 
The development of lymphomas in the mice injected with SLV at birth was 
directly  related  to  both  the  size  of  the  initial  inoculum  and  the  amount of 
continued viral replication as  measured by serum Mu gs-1  levels. Those mice 
with the highest Mu gs-1 levels were the first to develop lymphoma in the high 
dose groups in which all mice became lymphomatous. In the intermediate groups 
having only some mice that developed lymphomas, high Mu gs-1  levels again 
were  associated  with  tumor.  The  tumors  were  composed  almost  entirely  of 
thymic  antigen-positive virus-producing  cells,  suggesting  that  thymocytes or 
their precursor cells were among the SLV susceptible cells present in the newborn 
mice. Limitation of oncogenic infection to the neonatal period also suggests that 
recruitment  of tumor  cells  by  infection with  progeny  virus  later  in  life was 
unlikely.  An  attractive  explanation  of these  results  is  that  a  proportion  of 
susceptible  thymus  cells  was  infected  neonatally and  that  these  same  cells 
underwent  malignant  transformation  and  produced  the  tumors  in  the  adult CROKER, DEL VILLANO, JENSEN, LERNER, AND DIXON  1043 
FI6. 13.  Group l0  s, two glomeruli stained for C3. Extensively injured glomeruli, again out- 
lining capillary loops in addition to mesangial staining (x 540). 
animals.  This  hypothesis also  explains  the  effect of virus  dose  on  the  latent 
period; the fewer infected cells present originally, the longer was the time before 
oncogenesis and the production of an observable tumor mass. A host permissive 
to  viral  infection was  essential for oncogenesis  as  indicated  by the  failure of 
control groups of (BALB/c x  NZB)F1 mice receiving live AKR virus, killed SLV 
at birth, or live SLV at 6 wk of age to develop elevated Mu gs-1 titers or tumors. 
The coexistence of strong pathogenic immune responses and the development 
of lymphomas as a result of SLV infection might not have been expected in view 
of the instances in which MuLV infection has been reported to suppress immune 
responsiveness to certain exogenous antigens (for review, 24).  However, only in 
animals with advanced infections or large tumors were ANA levels seen to fall. 
Thus,  these  SLV  neonatal  infections  induced  ANA  and  antiviral  antibody 
responses in spite of any immunosuppression they might have caused. Perhaps 
some time after infection, the mice would have responded poorly to other new 
antigens, but their levels of ANA increased for at least 3-4 mo. In this situation, 
the immunogenicity and/or adjuvanticity of the infection apparently outweighed 
any immunosuppression for at least several months. 1044  IMMUNOPATHOGENICITY AND ONCOGENICITY IN MICE 
FIG. 14.  Group  103, glomerulus with  leukemic infiltrate in  the  surrounding parenchyma, 
stained for Mu  gs-1.  Note staining of capillary loops within the glomerular corpuscle and 
cytoplasmic staining of the leukemic cells in the infiltrate (× 570). 
It appears that infection with a number of murine oncornaviruses can cause the formation 
of  ANA  and  the  development  of  glomerulonephritis.  We  have  observed  that  MuLV 
Moloney has  immunopathologic effects generally similar to  those  of SLV. * Cannat and 
Varet (25) have reported ANA induction but not glomerulonephritis by Friend-Moloney- 
Rauscher (FMR) group MuLV in (BALB/c  ×  C57BL/6)F1 and (C3H  ×  C57BL/6)FI mice 
but not in the three parental strains. Glomerulonephritis has been reported in association 
with leukemia induced by the FMR group of viruses (26, 27).  Further, it appears that the 
glomerulonephritis that develops spontaneously in aging mice of several strains is immune 
complex  in  type  and  associated  with  MuLV  antigens  (28-32).  It  should  also  be 
remembered  that  other  virus  infections  such  as  lymphocytic  choriomeningitis  and 
polyoma may cause or enhance ANA and immune complex-type glomerulonephritis (33). 
Whether  the  different  oncornaviruses  differ  significantly  in  their  ability  to  cause 
immunologic  disease  or  whether  this  ability  is  related  only  to  the  degree  of  virus 
production  cannot  be  answered  at  present.  It  is  tempting  to  anticipate  that  an 
2 Croker, Jr., B. P.,  B. C. Del Villano, F. C. Jensen, R. A. Lerner, and F. J. Dixon.  Manuscript 
in preparation. CROKER,  DEL  VILLANO, JENSEN,  LERNER,  AND  DIXON  1045 
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oncornavirus isolated from a strain of mice with spontaneous immunologic disease (such 
as the  NZ) might be particularly prone to induce such disorders.  However, before such 
conjecture  is  warranted,  rigid  quantitatiVe  comparisons  of the  various  oncornaviruses 
must be made in a number of murine strains. Thus, for the present our observations are 
best considered a demonstration of the immunopathologic potential of oncornaviruses and 
not an indication of any special properties of an oncornavirus isolated from NZB mice. 
Summary 
This  report  clearly  demonstrates  that  a  systemic  lupus  erythematosus  (SLE)- 
like  syndrome  and  lymphoma  can  be  induced  in  immunologically  normal 
(BALB/c  ×  NZB)F1 mice by infection of neonates with a murine leukemia virus 
(MuLV)  (Scripps  leukemia virus  [SLV] 60A)  isolated from NZB lymphoblasts. 
SLV 60A was titered in vitro (XC test) and administered to newborn and adult 
(BALB/c  ×  NZB)F1  mice over six log10 dilutions.  Propagation  of MuLV  in the 
newborn recipients was indicated by greatly elevated serum Mu gs-1 levels which 
were proportional to the  dose of virus given. 1046  IMMUNOPATHOGENICITY  AND  ONCOGENICITY  IN MICE 
The  SLE-like  syndrome  was  characterized  by antinuclear  antibodies  (ANA) 
and  immune complex-type glomerulonephritis.  ANA production  was related to 
the  dose  of virus  and  reached  the  highest  levels  at  8-16  wk.  The  incidence  of 
glomerulonephritis was also correlated with the dose of virus and reached nearly 
50% in the animals given the highest virus dose. Both titers of ANA and incidence 
of  glomerulonephritis  were  greater  in  females  than  in  males,  although  the 
amounts  of Mu  gs-1  in  sera  of both  sexes  were  equal.  The  incidence  of direct 
Coombs' positivity was not significantly affected by inoculation  of this virus. 
The incidence and time of onset of thymocytic lymphoma were linearly related 
to  the  amount  of  virus  inoculated.  High  serum  Mu  gs-1  levels  predicted 
lymphoma development and reflected increases in the amount of infectious virus 
in  the  spleen.  No  induction  of tumors,  autoimmunity,  or high  serum  Mu  gs-1 
levels followed administration  of SLV 60A to 6-wk old (BALB/c  x  NZB)FI mice 
or inactivated  60A or active AKR virus to newborns. 
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